- Home
- LXU vs STOK Comparison
LXU vs STOK Comparison
Compare LXU & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LXU
- STOK
- Stock Information
- Founded
- LXU 1968
- STOK 2014
- Country
- LXU United States
- STOK United States
- Employees
- LXU N/A
- STOK N/A
- Industry
- LXU Major Chemicals
- STOK Biotechnology: Pharmaceutical Preparations
- Sector
- LXU Industrials
- STOK Health Care
- Exchange
- LXU Nasdaq
- STOK Nasdaq
- Market Cap
- LXU 494.2M
- STOK 556.7M
- IPO Year
- LXU 1969
- STOK 2019
- Fundamental
- Price
- LXU $6.52
- STOK $6.78
- Analyst Decision
- LXU Strong Buy
- STOK Strong Buy
- Analyst Count
- LXU 4
- STOK 8
- Target Price
- LXU $10.75
- STOK $23.83
- AVG Volume (30 Days)
- LXU 392.7K
- STOK 868.5K
- Earning Date
- LXU 04-28-2025
- STOK 03-18-2025
- Dividend Yield
- LXU N/A
- STOK N/A
- EPS Growth
- LXU N/A
- STOK N/A
- EPS
- LXU N/A
- STOK N/A
- Revenue
- LXU $522,400,000.00
- STOK $36,555,000.00
- Revenue This Year
- LXU $5.83
- STOK N/A
- Revenue Next Year
- LXU $7.54
- STOK N/A
- P/E Ratio
- LXU N/A
- STOK N/A
- Revenue Growth
- LXU N/A
- STOK 316.34
- 52 Week Low
- LXU $6.43
- STOK $7.06
- 52 Week High
- LXU $10.40
- STOK $17.58
- Technical
- Relative Strength Index (RSI)
- LXU 35.18
- STOK 32.89
- Support Level
- LXU $6.73
- STOK $7.18
- Resistance Level
- LXU $7.05
- STOK $8.45
- Average True Range (ATR)
- LXU 0.23
- STOK 0.57
- MACD
- LXU 0.00
- STOK -0.06
- Stochastic Oscillator
- LXU 0.00
- STOK 13.17
About LXU LSB Industries Inc.
LSB Industries Inc is engaged in the manufacturing and sale of chemical products in the United States. The company manufactures and sells chemical products for the agricultural and industrial sectors. Its products include ammonia, fertilizer grade ammonium nitrate (AN and HDAN), and urea ammonia nitrate (UAN) for agricultural applications; high purity and commercial grade ammonia, sulfuric acids, concentrated, blended, and regular nitric acid, mixed nitrating acids, carbon dioxide, and diesel exhaust fluid for industrial applications; and industrial grade AN (LDAN) and AN solutions for mining applications. Its products are sold through distributors and directly to end customers throughout the United States and other parts of North America.
About STOK Stoke Therapeutics Inc.
Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. The company primarily operates in the U.S.